Niki BioSolutions Accelerates Its Alzheimer’s Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics

Niki BioSolutions (NIKI) announced that its subsidiary DiamiR Biosciences has engaged Fios Genomics to provide bioinformatics and biostatistical analysis for its Alzheimer’s disease testing program.

Rhea-AI Summary

Niki BioSolutions (NIKI) announced that its subsidiary DiamiR Biosciences has engaged Fios Genomics to provide bioinformatics and biostatistical analysis for its Alzheimer’s disease testing program.

Fios Genomics will analyze and interpret multi-omics and other complex biological datasets generated across the program, aiming to sharpen target and biomarker decisions and help advance Niki’s Alzheimer’s assays through the development pipeline. The company highlights that rigorous, reproducible analysis is essential for identifying meaningful biological signals, validating biomarkers, and guiding decisions at each stage of development.

Under the engagement, Fios Genomics will deliver end-to-end analytical support, including data quality assessment, statistical analysis and interpretation of current datasets, and clear, decision-ready reports for Niki’s research and development team. The resulting insights are expected to inform target and biomarker prioritization and support the design of subsequent validation studies within the Alzheimer’s pipeline.

Argus 15 min delay

-0.94% vs previous close $5.66 last price 34.3x rel. volume Open Argus

Details

Market Reaction – NIKI

+6.7% Peak in 3 min

$5.66 $6.35 Day Range

$4.61M Market Cap

Following this news, NIKI has declined 0.94%, reflecting a mild negative market reaction. Argus tracked a peak move of +6.7% during the session. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $5.66. Trading volume is exceptionally heavy at 34.3x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

A Jul 23 partnership announcement was followed by a -4.56% 24-hour move; this engagement also involv...

Analysis

A Jul 23 partnership announcement was followed by a -4.56% 24-hour move; this engagement also involved DiamiR and Alzheimer’s research but addressed bioinformatics rather than APOE testing.

Previous Partnership Reports

1 past event · Latest: Jul 23

Same Type 1 event

1. Jul 23

   Partnership agreement

   24h Move

   -4.6%

   DiamiR agreed to provide APOE genotyping services for Alzheimer’s research programs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

multi-omics, bioinformatics, biostatistics, transcriptomic, +1 more

5 terms

multi-omics technical

"Advanced multi-omics data analysis and biostatistical expertise"

Multi-omics is a comprehensive approach that combines different types of biological data—such as genetic information, proteins, and other molecules—to gain a detailed understanding of how living systems function. For investors, this approach can reveal insights into health, disease, or biological processes that may influence the development of new treatments or technologies, potentially impacting market opportunities and innovation in healthcare.

bioinformatics technical

"a specialist provider of bioinformatics and biostatistics services"

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

biostatistics technical

"a specialist provider of bioinformatics and biostatistics services"

Biostatistics is the use of statistical methods to design medical studies, analyze biological and health data, and interpret the reliability of results from clinical trials and observational research. For investors, it is the tool that turns raw trial numbers into clear probabilities and confidence levels—much like a weather forecast turns measurements into a prediction—helping assess how credible study results are, estimate development risk, and value potential outcomes.

transcriptomic technical

"genomic, transcriptomic, proteomic, and other large, complex biological datasets"

Transcriptomic describes anything related to the transcriptome — the complete set of RNA messages a cell or tissue makes at a given time, which shows which genes are actively being used. Think of it like a snapshot of which recipes are being cooked in a kitchen; for investors, transcriptomic data matters because it helps identify drug targets, predict treatment response, and validate whether a therapy is affecting biology as intended, all of which can change a company’s development prospects and valuation.

proteomic technical

"genomic, transcriptomic, proteomic, and other large, complex biological datasets"

Proteomic describes something related to the large-scale study of proteins—the working parts inside cells that carry out functions and signal changes. For investors, proteomic work can reveal new drug targets, diagnostic tests or biomarkers that change a company’s potential revenue and risk profile; think of it like analyzing all ingredients in a recipe to find which ones can be improved or swapped to make a better product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform

PRINCETON, N.J., and NEW HAVEN, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that its wholly owned subsidiary, DiamiR Biosciences Corp. (“DiamiR”), has engaged Fios Genomics, a specialist provider of bioinformatics and biostatistics services, to perform bioinformatics and statistical analysis in support of the Company’s Alzheimer’s disease program. Under the engagement, Fios Genomics will analyze and interpret data generated across the program to help Niki BioSolutions advance its Alzheimer’s assays through the development pipeline.

Alzheimer’s disease affects tens of millions of people worldwide and remains one of the most significant unmet needs in medicine. Robust, reproducible analysis of complex biological datasets is essential to identifying meaningful biological signals, validating targets and biomarkers, and making well-informed decisions at each stage of development. Fios Genomics brings deep experience in the analysis of genomic, transcriptomic, proteomic, and other large, complex biological datasets, together with rigorous statistical methodology, to help translate raw data into actionable insight.

“Engaging Fios Genomics is an important step forward for our Alzheimer’s program,” said Alidad Mireskandari, Ph.D., President and Chief Operating Officer of Niki BioSolutions. “The datasets generated in this project are large and complex, and getting the analysis right is critical to the decisions we make next. Fios Genomics has a strong track record of delivering high-quality, independent bioinformatics and statistical analysis for life sciences organizations, and its expertise allows our team to stay focused on advancing the science. We look forward to a productive collaboration as we work to bring new options to people at risk of or living with Alzheimer’s disease.”

As part of the engagement, Fios Genomics will provide end-to-end analytical support, including data quality assessment, statistical analysis and interpretation of current datasets, and the delivery of clear, decision-ready reports to Niki BioSolutions’ research and development team. The work is expected to inform target and biomarker prioritization and support the design of subsequent validation studies within the pipeline.

About Niki BioSolutions

Niki BioSolutions is a clinical-stage life sciences company focused on unmet medical needs and on providing high-quality genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations through its CLIA-certified, CAP-accredited laboratory. The company combines proprietary technologies with a commitment to scientific rigor to support precision medicine across a range of therapeutic areas, including brain health and oncology. Niki BioSolutions collaborates with leading academic centers, disease foundations, and biopharma companies.

About Fios Genomics

Fios Genomics is a specialist provider of bioinformatics and biostatistics services to the pharmaceutical, biotechnology, and academic sectors. The company supports research and development programs with data analysis and interpretation across genomics, transcriptomics, proteomics, and other high-throughput data types, from early discovery through clinical development. Fios Genomics is headquartered in Edinburgh, United Kingdom. For more information, visit www.fiosgenomics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, Niki BioSolutions’ ability to successfully operate its business and provide value to stockholders; Niki BioSolutions’ future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing or future ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Niki BioSolutions and its industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Niki BioSolutions operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Niki BioSolutions operates, the financial markets, economic, business and regulatory factors, and other factors, such as Niki BioSolutions’ ability to execute on its strategies. More detailed information about risk factors can be found in the registration statement on Form S-4 filed with the Securities and Exchange Commission (the “SEC”) on October 6, 2025 (File No. 333-290742), and in other reports filed under the company’s prior name, Aptorum Group Limited, and that will be filed by Niki BioSolutions with the SEC. Niki BioSolutions does not undertake any duty to update forward-looking statements after the date of this press release.

Investor Contact:

Lytham Partners, LLC
Ben Shamsian
646-829-9701
shamsian@lythampartners.com